pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

28,934 catalysts · 9,606 approval · 5,000 device 510k · 4,728 grant · 2,809 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-03: 0 catalysts2026-08-04: 0 catalysts2026-08-05: 97 catalysts2026-08-06: 18 catalysts2026-08-07: 2 catalysts2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 3 catalysts2026-08-11: 2 catalysts2026-08-12: 3 catalysts2026-08-13: 3 catalysts2026-08-14: 1 catalyst2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 2 catalysts2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 1 catalyst2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 0 catalysts2026-10-27: 3 catalysts2026-10-28: 4 catalysts2026-10-29: 9 catalysts2026-10-30: 3 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2017-08-21×clear all
type
  • approval9,606
  • device 510k5,000
  • grant4,728
  • 8k filing2,809
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings364
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Sep 17, 2018

    2
    ›Sep 21, 2018approval2876d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: WES PHARMA INC. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Sep 21, 2018approval2876d agoOXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: PH HEALTH. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗

    Week of Sep 24, 2018

    9
    ›Sep 24, 2018approval2873d agoCOPIKTRA (DUVELISIB) — FDA approvalSecura Bio Inc

    Sponsor: SECURA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Sep 24, 2018approval

    Week of Oct 1, 2018

    3
    ›Oct 3, 2018approval2864d agoENBREL (ETANERCEPT) — FDA approvalAMGEN INC

    Sponsor: IMMUNEX. Form: SYRINGE

    full page →fda approvals ↗
    ›Oct 4, 2018approval

    Week of Oct 8, 2018

    5
    ›Oct 9, 2018approval2858d agoSILIQ (BRODALUMAB) — FDA approvalBausch Health US LLC

    Sponsor: VALEANT LUXEMBOURG. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Oct 10, 2018approval

    Week of Oct 15, 2018

    11
    ›Oct 16, 2018approval2851d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Oct 16, 2018approval

    Week of Oct 22, 2018

    13
    ›Oct 23, 2018approval2844d agoOXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: RHODES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 24, 2018approval

    Week of Oct 29, 2018

    7
    ›Oct 29, 2018approval2838d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: HIBROW HLTHCARE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 29, 2018approval
    ← prev
    page 20 of 579
    next →
    2873d ago
    COPIKTRA (DUVELISIB) — FDA approvalSecura Bio Inc

    Sponsor: SECURA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Sep 25, 2018approval2872d agoBENAZEPRIL HYDROCHLORIDE — FDA approvalBENAZEPRIL HYDROCHLORIDE

    Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL

    full page →BENAZEPRIL HYDROCHLORIDE →fda approvals ↗
    ›Sep 26, 2018approval2871d agoOXYCONTIN (OXYCODONE HYDROCHLORIDE) — FDA approvalOXYCODONE HYDROCHLORIDE

    Sponsor: PURDUE PHARMA LP. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →OXYCODONE HYDROCHLORIDE →fda approvals ↗
    ›Sep 26, 2018approval2871d agoAMPHETAMINE SULFATE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 28, 2018approval2869d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: IMPAX LABS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Sep 28, 2018approval2869d agoHUMIRA (ADALIMUMAB) — FDA approvaladalimumab

    Sponsor: ABBVIE INC. Form: VIAL

    full page →adalimumab →fda approvals ↗
    ›Sep 28, 2018approval2869d agoARIKAYCE KIT (AMIKACIN SULFATE) — FDA approvalamikacin sulfate PR

    Sponsor: INSMED INC. Form: SUSPENSION, LIPOSOMAL. Route: INHALATION

    full page →amikacin sulfate PR →fda approvals ↗
    ›Sep 28, 2018approval2869d agoLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalcemiplimab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INTRAVENOUS

    full page →cemiplimab →fda approvals ↗
    2863d ago
    VFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 5, 2018approval2862d agoPYLERA (BISMUTH SUBCITRATE POTASSIUM) — FDA approval

    Sponsor: LABS JUVISE. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    2857d ago
    SPINRAZA (NUSINERSEN SODIUM) — FDA approvalBIOGEN INC.

    Sponsor: BIOGEN IDEC. Form: SOLUTION. Route: INTRATHECAL

    full page →fda approvals ↗
    ›Oct 11, 2018approval2856d agoCHILDREN'S ZYRTEC HIVES (CETIRIZINE HYDROCHLORIDE) — FDA approvalKenvue Inc.

    Sponsor: KENVUE BRANDS. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 12, 2018approval2855d agoCAPRELSA (VANDETANIB) — FDA approvalvandetanib

    Sponsor: GENZYME CORP. Form: TABLET. Route: ORAL

    full page →vandetanib →fda approvals ↗
    ›Oct 12, 2018approval2855d agoOXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: RHODES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    2851d ago
    HUMIRA (ADALIMUMAB) — FDA approvaladalimumab

    Sponsor: ABBVIE INC. Form: VIAL

    full page →adalimumab →fda approvals ↗
    ›Oct 16, 2018approval2851d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Oct 16, 2018approval2851d agoOXALIPLATIN — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: NOVAST LABS. Form: INJECTABLE. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Oct 17, 2018approval2850d agoVISINE (NAPHAZOLINE HYDROCHLORIDE) — FDA approval

    Sponsor: KENVUE BRANDS. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →fda approvals ↗
    ›Oct 18, 2018approval2849d agoXELJANZ XR (TOFACITINIB CITRATE) — FDA approvaltofacitinib citrate ER

    Sponsor: PFIZER. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →tofacitinib citrate ER →fda approvals ↗
    ›Oct 18, 2018approval2849d agoXELJANZ (TOFACITINIB CITRATE) — FDA approvalBiocon Pharma Ltd

    Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 18, 2018approval2849d agoBOSULIF (BOSUTINIB MONOHYDRATE) — FDA approvalAlembic Pharmaceuticals Inc

    Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 18, 2018approval2849d agoICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approvalTakeda Pharmaceuticals USA Inc

    Sponsor: TAKEDA PHARMS USA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 19, 2018approval2848d agoDUPIXENT (DUPILUMAB) — FDA approvaldupilumab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

    full page →dupilumab →fda approvals ↗
    ›Oct 19, 2018approval2848d agoSAXENDA (LIRAGLUTIDE) — FDA approvalNovo Nordisk Inc

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    2843d ago
    HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: ALVOGEN. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Oct 24, 2018approval2843d agoIRBESARTAN — FDA approvalIRBESARTAN

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →IRBESARTAN →fda approvals ↗
    ›Oct 25, 2018approval2842d agoTRACLEER (BOSENTAN) — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

    Sponsor: ACTELION. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 25, 2018approval2842d agoTRACLEER (BOSENTAN) — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

    Sponsor: ACTELION. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 25, 2018approval2842d agoAFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approvalinsulin human

    Sponsor: MANNKIND. Form: POWDER. Route: INHALATION

    full page →insulin human →fda approvals ↗
    ›Oct 26, 2018approval2841d agoSUBOXONE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: INDIVIOR. Form: FILM. Route: BUCCAL, SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›Oct 26, 2018approval2841d agoXTAMPZA ER (OXYCODONE) — FDA approvaloxycodone ER

    Sponsor: COLLEGIUM PHARM INC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →oxycodone ER →fda approvals ↗
    ›Oct 26, 2018approval2841d agoSYNJARDY XR (EMPAGLIFLOZIN) — FDA approval(empagliflozin + metformin hydrochloride ER)

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →(empagliflozin + metformin hydrochloride ER) →fda approvals ↗
    ›Oct 26, 2018approval2841d agoGLYXAMBI (EMPAGLIFLOZIN) — FDA approval(empagliflozin + linagliptin)

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

    full page →(empagliflozin + linagliptin) →fda approvals ↗
    ›Oct 26, 2018approval2841d agoSYNJARDY (EMPAGLIFLOZIN) — FDA approvalSYNJARDY

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

    full page →SYNJARDY →fda approvals ↗
    ›Oct 26, 2018approval2841d agoJARDIANCE (EMPAGLIFLOZIN) — FDA approvalSYNJARDY

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

    full page →SYNJARDY →fda approvals ↗
    ›Oct 28, 2018approval2839d agoBIJUVA (ESTRADIOL) — FDA approval(estradiol + progesterone)

    Sponsor: MAYNE PHARMA. Form: CAPSULE. Route: ORAL

    full page →(estradiol + progesterone) →fda approvals ↗
    2838d ago
    OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: ASCENT PHARMS INC. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Oct 30, 2018approval2837d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Oct 30, 2018approval2837d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 30, 2018approval2837d agoHYRIMOZ (ADALIMUMAB-ADAZ) — FDA approvalHYRIMOZ

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →HYRIMOZ →fda approvals ↗
    ›Oct 31, 2018approval2836d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalIGC Pharma, Inc.

    Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL

    full page →fda approvals ↗
    ›Oct 31, 2018approval2836d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: RUBICON RESEARCH. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    $IGC0.2670+0.41%
    $AMRX18.46-0.11%
    $AMGN407.83+4.57%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $AMRX18.46-0.11%
    $ABBV246.20+0.98%
    $KVUE19.67+0.61%
    $AMRX18.46-0.11%
    $BIIB206.63-0.87%
    $INSM99.02+0.27%
    $REGN768.58+1.04%
    $IGC0.2670+0.41%
    $INDV40.10-2.17%
    $MNKD4.1000+3.54%
    $ABBV246.20+0.98%
    $REGN768.58+1.04%
    $PFE25.81+1.57%
    $PYPD4.6000+3.37%
    $COLL35.74+0.03%
    $IGC0.2670+0.41%